Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034487 | 1.00 | KMT2A (0.57) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL12170406 | 1.00 | KMT2A (0.57) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL28742797 | 0.86 | GSK3B (0.61) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL28958998 | 0.84 | KMT2A (0.51) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL6157208 | 0.83 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL6157212 | 0.83 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL6157204 | 0.83 | ALDH1A1 (0.51) | KMT2AMEN1CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL7398 | 0.80 | KMT2A (0.64) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL2438088 | 0.77 | POLB (0.50) | KMT2AMEN1L3MBTL1HPGDMAPT | |
| SCHEMBL2438089 | 0.77 | POLB (0.50) | KMT2AMEN1L3MBTL1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4241/4885MEN1 4705/4885CYP1A2 1815/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MEN1 3803/4885CYP1A2 2933/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | KMT2A 3156/4885MEN1 4355/4885CYP1A2 1024/4885 |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KMT2A 4241/4885MEN1 4705/4885CYP1A2 1815/4885 |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4241/4885MEN1 4705/4885CYP1A2 1815/4885 |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KMT2A 4241/4885MEN1 4705/4885CYP1A2 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.